Home METALS Stocks In News: GenVec Inc, ZIOPHARM Oncology Inc, Dole Food Company Inc, FuelCell Energy Inc

Stocks In News: GenVec Inc, ZIOPHARM Oncology Inc, Dole Food Company Inc, FuelCell Energy Inc

0
0

GenVec Inc (NASDAQ:GNVC) shares declined 36.80% to $0.455 in the morning hour. The company on May 28 announced that on May 24 its board approved a plan of complete liquidation and dissolution of the company, saying that it is in the best interests of the company and its stockholders.

The company said, if the company’s stockholders approve the Plan of Dissolution, that it plans to file a certificate of dissolution with the Delaware Secretary of State, complete the liquidation of the Company’s assets, satisfy the Company’s remaining obligations and make distributions to the Company’s stockholders of any available liquidation proceeds.

Is GNVC a Buy After The Recent Gain? Find Out Here

ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) shares decreased 4.69% to $2.50. The company, on May 7, announced financial results for the first quarter ended March 31, 2013, and provided an update on the Company’s key developments. ZIOPHARM reported a GAAP net loss of $12.8 million for the first quarter of 2013, or $(0.15) per share, compared to a GAAP net loss of $24.5 million, or $(0.32) per share, in the first quarter of 2012.

Dole Food Company, Inc.(NYSE:DOLE) shares declined 6.15% to $10.38. The company on May 28 announced that its Board of Directors has approved updating the Company’s owned vessel fleet, with the acquisition of three new specialty built refrigerated container ships for its U.S. West Coast operations, costing approximately $165 million, for a phased delivery in the late 2015 to early 2016 time frame.

FuelCell Energy, Inc. (NASDAQ:FCEL) shares dropped 3.37% to $1.47. The company announced it will release its second quarter 2013 financial results after the Market Close on Wednesday, June 5, 2013. FuelCell Energy management will host a conference call with investors beginning at 10:00 a.m. Eastern Time on June 6, 2013 to discuss the second quarter 2013 results.